[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100391270":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":30,"centralContacts":35,"locations":41,"responsibleParty":80,"collaborators":30,"id":82,"slug":83,"hasResults":84,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":30,"eligibilityCriteria":88,"healthyVolunteers":84,"sex":89,"minAge":90,"maxAge":30,"enrollmentInfo":91,"targetDuration":30,"studyType":94,"phases":95,"briefSummary":97,"conditions":98,"keywords":30,"overallStatus":44,"whyStopped":30,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":109},{"fullName":5,"class":6},"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Low dose heparin","ACTIVE_COMPARATOR","heparin (25 IU\u002FKg -maximal dose 3,000 IU)",[13],"Drug: Heparin",{"label":15,"type":10,"description":16,"interventionNames":17},"High dose heparin","heparin 50 IU\u002Fkg -maximal dose 5,000 IU",[13],{"label":19,"type":20,"description":21,"interventionNames":22},"Placebo","PLACEBO_COMPARATOR","Normal saline 0.9%.",[23],"Drug: Placebos",[25,31],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"DRUG","Heparin","two doses of heparin",[15,9],null,{"type":26,"name":32,"description":33,"armGroupLabels":34,"otherNames":30},"Placebos","placebo",[19],[36],{"name":37,"role":38,"phone":39,"phoneExt":30,"email":40},"Shahar Lavi, MD","CONTACT","519-6633611","Shahar.lavi@lhsc.on.ca",[42,61],{"facility":43,"status":44,"city":45,"state":46,"zip":30,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Hamilton Health Sciences","RECRUITING","Hamilton","Ontario","Canada","CA",{"type":50,"coordinates":51},"Point",[52,53],-79.84963,43.25011,{"lat":53,"lon":52},[56,58],{"name":57,"role":38,"phone":30,"phoneExt":30,"email":30},"Shamir Mehta",{"name":59,"role":60,"phone":30,"phoneExt":30,"email":30},"Shamir Mehta, MD","PRINCIPAL_INVESTIGATOR",{"facility":62,"status":44,"city":63,"state":46,"zip":64,"country":47,"countryCode":48,"cosmosGeoPoint":65,"geoPoint":69,"contacts":70},"London Health Sciences Centre","London","N6A5A5",{"type":50,"coordinates":66},[67,68],-81.23304,42.98339,{"lat":68,"lon":67},[71,74,79],{"name":37,"role":38,"phone":72,"phoneExt":30,"email":73},"519-663-3611","shahar.lavi@lhsc.on.ca",{"name":75,"role":38,"phone":76,"phoneExt":77,"email":78},"Cassandra Wagner, MSc","519-685-8500","35625","cassandra.wagner@lhsc.on.ca",{"name":37,"role":60,"phone":30,"phoneExt":30,"email":30},{"type":81,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR","100391270","phase-3-heparin-vs-placebo-for-cardiac-catheterization-100391270",false,"NCT04374799","Heparin vs Placebo for Cardiac Catheterization","A Randomized Trial of Heparin vs Placebo in Patients Undergoing Cardiac Catheterization Via the Trans-radial Approach","Inclusion Criteria:\n\n* diagnostic cardiac catheterization; Small size sheath; patency of the ulno-palmar circulation\n\nExclusion Criteria:\n\nabnormal ulno-palmar circulation; Prior radial artery thrombosis; Prior surgery close to the access site; Emergent cardiac catheterization; History of HIT or allergy to heparin; Patients requiring anticoagulation","ALL","18 Years",{"count":92,"type":93},1623,"ESTIMATED","INTERVENTIONAL",[96],"PHASE3","Patients undergoing cardiac catheterization will be randomized to 3 groups: no anticoagulant, low dose anticoagulant and high dose anticoagulant.",[99],"Cardiac Disease","2026-02-18",{"date":102,"type":103},"2026-02-20","ACTUAL",{"date":105,"type":103},"2020-10-05",{"date":107,"type":93},"2026-12",{"name":5,"class":6},2]